A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (mai
- This topic has 0 replies, 1 voice, and was last updated 2 years, 6 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (maint) ivaltinostat (ival) plus capecitabine (cap) or capecitabine monotherapy in patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) whose disease has not progressed on first-line FOLFIRINOX chemotherapy (CT).
https://meetings.asco.org/abstracts-presentations/213168
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.